Integrated Quantitative Investments LLC Makes New $377,000 Investment in Solventum Co. (NYSE:SOLV)

Integrated Quantitative Investments LLC bought a new stake in Solventum Co. (NYSE:SOLV) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 5,700 shares of the company’s stock, valued at approximately $377,000.

A number of other institutional investors and hedge funds have also modified their holdings of SOLV. New York Life Investment Management LLC increased its stake in Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock worth $1,223,000 after buying an additional 136 shares in the last quarter. Blue Trust Inc. lifted its holdings in Solventum by 2.1% in the 4th quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after purchasing an additional 161 shares in the last quarter. MML Investors Services LLC boosted its stake in Solventum by 3.2% during the 3rd quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock worth $373,000 after purchasing an additional 168 shares during the last quarter. Avantax Advisory Services Inc. grew its holdings in shares of Solventum by 2.2% during the fourth quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after buying an additional 192 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Solventum by 48.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 687 shares of the company’s stock valued at $45,000 after buying an additional 223 shares during the last quarter.

Solventum Stock Performance

NYSE:SOLV opened at $66.22 on Friday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $85.92. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The company has a 50 day moving average price of $75.42 and a 200 day moving average price of $71.95. The stock has a market capitalization of $11.45 billion and a P/E ratio of 24.08.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Bank of America lifted their price objective on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised their target price on Solventum from $73.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. Piper Sandler boosted their price target on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Finally, Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.